Sethi Amrita, Shiffman Mitchell L
Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA.
Clin Liver Dis. 2005 Aug;9(3):453-71, vii-viii. doi: 10.1016/j.cld.2005.05.002.
The combination of peginterferon and ribavirin is the most effective therapy for patients with chronic hepatitis C virus (HCV) infection. Although more than half of all patients are able to achieve a sustained virologic response (SVR), a significant proportion of patients, particularly those with genotype 1, fail to have undetectable HCV RNA during treatment or relapse after completing therapy with return of detectable HCV RNA. The management of these patients creates a formidable challenge. This article outlines various strategies for patients who have failed to achieve SVR and discusses the merits of different approaches to management.
聚乙二醇干扰素与利巴韦林联合使用是慢性丙型肝炎病毒（HCV）感染患者最有效的治疗方法。尽管超过半数的患者能够实现持续病毒学应答（SVR），但仍有相当一部分患者，尤其是基因1型患者，在治疗期间无法使HCV RNA检测不到，或在完成治疗后复发，HCV RNA再次可检测到。对这些患者的管理带来了巨大挑战。本文概述了未实现SVR的患者的各种策略，并讨论了不同管理方法的优点。
